Castle Biosciences (CSTL) Amortization - Intangibles (2021 - 2026)

Castle Biosciences has reported Amortization - Intangibles for 6 years, with the latest figure at $2.3 million in Q2 2026.

• Quarterly Amortization - Intangibles rose 15.0% year-over-year to $2.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.1 million (down 73.9% YoY) and the FY2025 annual result came in at $34.8 million, up 213.69% from the prior year.
• Amortization - Intangibles improved to $2.3 million in Q2 2026 per CSTL's latest filing, from $2.2 million in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $28.3 million in Q1 2025 and troughed at $1.6 million in Q1 2022.
• A 5-year average of $3.6 million and a median of $2.2 million in 2024 frame the typical range for Amortization - Intangibles.
• The sharpest annual moves came in 2025 and 2026: Amortization - Intangibles surged 1160.57% in 2025, then plunged 92.14% in 2026.
• Over 5 years, Amortization - Intangibles stood at $2.2 million in 2022, then advanced by 3.23% to $2.3 million in 2023, then decreased by 7.53% to $2.1 million in 2024, then increased by 6.57% to $2.2 million in 2025, then increased by 2.77% to $2.3 million in 2026.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $2.3 million, $2.2 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.